Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:11615 |
Name | penile cancer |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:11614 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer penile cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Pembrolizumab | penile cancer | sensitive | detail... |
MSH6 negative | Pembrolizumab | penile cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02426892 | Phase II | Nivolumab | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | Completed | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02812056 | Phase I | Alisertib + Sapanisertib | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | Withdrawn | 0 | |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT03260023 | Phase Ib/II | Avelumab Avelumab + Tipapkinogene sovacivec | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Active, not recruiting | USA | FRA | ESP | 0 |
NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT03427411 | Phase II | Bintrafusp alfa | Phase II Trial of M7824 in Subjects With HPV Positive Malignancies | Completed | USA | 0 |
NCT03439085 | Phase II | Durvalumab + MEDI0457 | Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers | Terminated | USA | 0 |
NCT03618953 | Phase I | Ad-E6E7 + Atezolizumab + MG1-E6E7 | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher) | Terminated | USA | CAN | 0 |
NCT03866382 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors | Recruiting | USA | 1 |
NCT04287868 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Active, not recruiting | USA | 0 |
NCT04432597 | Phase Ib/II | PRGN-2009 Bintrafusp alfa + PRGN-2009 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | Active, not recruiting | USA | 0 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Recruiting | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT05526989 | Phase II | Dostarlimab-gxly + Niraparib | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |